GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (STU:3371) » Definitions » Cash Flow from Others

Corbus Pharmaceuticals Holdings (STU:3371) Cash Flow from Others : €-2.11 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Cash Flow from Others?

Corbus Pharmaceuticals Holdings's cash flow from others for the three months ended in Mar. 2025 was €-0.22 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2025 was €-2.11 Mil.


Corbus Pharmaceuticals Holdings Cash Flow from Others Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Cash Flow from Others Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 1.26 1.53 0.27 -2.62

Corbus Pharmaceuticals Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.81 -0.48 -0.60 -0.22

Corbus Pharmaceuticals Holdings Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.11 Mil.

Corbus Pharmaceuticals Holdings Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines